181 related articles for article (PubMed ID: 33394101)
1. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
Hurtado FK; de Braud F; De Castro Carpeño J; de Miguel Luken MJ; Wang D; Scott J; Lau YY; McCulloch T; Mau-Sorensen M
Cancer Chemother Pharmacol; 2021 Apr; 87(4):475-486. PubMed ID: 33394101
[TBL] [Abstract][Full Text] [Related]
2. [Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer].
Tian Y; Tian T; Yu P; Ren L; Gong Y; Yao W; Zhang X; Yin J; He L; Chen L; Wang K; Huang M; Li J
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):655-661. PubMed ID: 32838488
[TBL] [Abstract][Full Text] [Related]
3. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
[TBL] [Abstract][Full Text] [Related]
4. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors.
Hanley MJ; D'Arcangelo M; Felip E; Garrido P; Zhu J; Ye M; Vranceanu F; Gupta N
J Clin Pharmacol; 2023 May; 63(5):583-592. PubMed ID: 36579743
[TBL] [Abstract][Full Text] [Related]
6. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
7. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Tian W; Zhang P; Yuan Y; Deng XH; Yue R; Ge XZ
J Clin Pharm Ther; 2020 Aug; 45(4):743-754. PubMed ID: 32369239
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
10. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Cho BC; Obermannova R; Bearz A; McKeage M; Kim DW; Batra U; Borra G; Orlov S; Kim SW; Geater SL; Postmus PE; Laurie SA; Park K; Yang CT; Ardizzoni A; Bettini AC; de Castro G; Kiertsman F; Chen Z; Lau YY; Viraswami-Appanna K; Passos VQ; Dziadziuszko R
J Thorac Oncol; 2019 Jul; 14(7):1255-1265. PubMed ID: 30851442
[TBL] [Abstract][Full Text] [Related]
12. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
[TBL] [Abstract][Full Text] [Related]
13. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
Santoro A; Su WC; Navarro A; Simonelli M; Ch Yang J; Ardizzoni A; Barlesi F; Hyoung Kang J; DiDominick S; Abdelhady A; Chen X; Stammberger U; Felip E
Lung Cancer; 2022 Apr; 166():170-177. PubMed ID: 35298959
[TBL] [Abstract][Full Text] [Related]
15. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
17. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
[TBL] [Abstract][Full Text] [Related]
18. Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study.
Kaneda H; Kizaki M; Ochi M; Shiraiwa N; Akatsu S
Sci Rep; 2020 Oct; 10(1):16773. PubMed ID: 33033286
[TBL] [Abstract][Full Text] [Related]
19. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
[TBL] [Abstract][Full Text] [Related]
20. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Felip E; de Braud FG; Maur M; Loong HH; Shaw AT; Vansteenkiste JF; John T; Liu G; Lolkema MP; Selvaggi G; Giannone V; Cazorla P; Baum J; Balbin OA; Wang LV; Lau YY; Scott JW; Tan DS
J Thorac Oncol; 2020 Mar; 15(3):392-403. PubMed ID: 31634667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]